Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer

Artiva Biotherapeutics, Inc. ( (ARTV) ) has issued an announcement.

Artiva Biotherapeutics announced on February 24, 2026 that its board appointed veteran finance executive Thad Huston as chief financial officer, effective February 18, 2026, making him the company’s principal financial and accounting officer. Huston brings more than three decades of global leadership across pharmaceuticals, biotechnology and medical devices, including senior roles at Galapagos NV, Kite Pharma, LivaNova and Johnson & Johnson, which is expected to bolster Artiva’s financial strategy and operational discipline as it advances its therapeutic pipeline.

Under an employment agreement, Huston will receive a $540,000 annual base salary, a target annual bonus equal to 40% of base pay for 2026, and an inducement grant of 220,000 restricted stock units that vest over four years, aligning his compensation with long-term shareholder value. The agreement also provides tiered severance and accelerated equity vesting benefits in the event of certain terminations, including in connection with a change of control, signaling Artiva’s intent to secure stable senior financial leadership during potential strategic transactions and future growth phases.

The most recent analyst rating on (ARTV) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Artiva Biotherapeutics, Inc. stock, see the ARTV Stock Forecast page.

Spark’s Take on ARTV Stock

According to Spark, TipRanks’ AI Analyst, ARTV is a Neutral.

The score is held back primarily by collapsing revenue, persistent large losses, and escalating cash burn that increase financing risk. This is partially offset by strong recent technical trend/momentum and a positive clinical-trial update, while valuation remains constrained by negative earnings and no dividend signal.

To see Spark’s full report on ARTV stock, click here.

More about Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc. is a biotechnology company operating in the pharmaceutical and medical innovation space, focusing on developing advanced cell-based therapies, including oncology-focused treatments. The company competes in a rapidly evolving biotech landscape where experienced financial and operational leadership is critical to support capital-intensive R&D and potential commercialization efforts.

Average Trading Volume: 1,038,474

Technical Sentiment Signal: Buy

Current Market Cap: $101.9M

Learn more about ARTV stock on TipRanks’ Stock Analysis page.